PDCD1 and neoplasm: Currently, the classification of tumor immunity is almost exclusively based on the spatial distribution of CD8 + T cells in the tumor microenvironment (TME), which are targeted by immune checkpoint inhibitors of PD-1 thereby enhancing their anti-tumor functions [12].